Market Overview

Investigation Report on Chinese Atorvastatin Market, 2018-2022 -


The "Investigation
Report on Chinese Atorvastatin Market, 2018-2022"
report has
been added to's offering.

The number of patients with hyperlipidemia is increasing in China with
the lifestyle change resulting from the economic development and the
rise of residents' income. It is estimated that there are over 100
million patients with hyperlipidemia and 160 million patients with
dyslipidemia in China. And the figures are increasing every year.

Atorvastatin is a common drug that lowers blood cholesterol levels. It
was developed by Pfizer in the trade name of Lipitor. It has been proved
that Atorvastatin is safe and can decrease major cardiovascular events
for patients with coronary heart disease, ischemic stroke, diabetes and
high-risk patients with cardiovascular diseases such as hypertension. By
the end of 2017, the global sales of Lipitor had exceeded USD 150
billion, creating a miracle in global drug sales.

According to the researcher, Atorvastatin has been growing rapidly since
it entered China, with its sales revenue increasing from less than CNY
200 million in 2005 to more than CNY 2.21 billion in 2017. There is a
high demand for Atorvastatin in China. In addition to Pfizer's
brand-name drug Lipitor, generic drugs of Beijing Jialin Pharmaceutical
Co., Ltd., China Meheco Topfond Pharma Co., Ltd., Zhejiang Neo-Dankong
Pharmaceutical Co., Ltd., Guangdong Baike Pharmaceutical Co., Ltd., etc.
are also sold on the market. Pfizer captured the largest market share by
sales value. Its market share exceeded 70% with a sales value over CNY
1.6 billion in 2017.

It is estimated that the number of patients with hyperlipidemia will
continue to grow in China in the next few years, which will lead to a
rising demand for Atorvastatin.

Key Topics Covered:

1 Relevant Concepts of Atorvastatin

2 Sales of Atorvastatin in China, 2013-2017

3 Analysis On Major Atorvastatin Manufacturers in China, 2013-2017

4 Prices of Different Manufacturers' Atorvastatin in China, 2017-2018

5 Prospect of Chinese Atorvastatin Market, 2018-2022

Companies Mentioned

  • Pfizer
  • Beijing Jialin Pharmaceutical Co., Ltd.
  • China Meheco Topfond Pharma Co., Ltd.
  • Zhejiang Neo-Dankong Pharmaceutical Co., Ltd.
  • Guangdong Baike Pharmaceutical Co., Ltd.

For more information about this report visit

View Comments and Join the Discussion!